Published in Healthcare Mergers, Acquisitions and Ventures Week, April 21st, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Lupin Pharmaceuticals.
Report 1: Lupin Ltd. today announced that the US FDA has approved the Company's Abbreviated New Drug Application (ANDA) for Sertraline Hydrochloride Tablets, 25mg, 50mg and 100mg. Sertraline Hydrochloride is indicated for the treatment of major depressive disorder.
Lupin's Sertraline Tablets are the AB-rated generic equivalent of Pfizer's Zoloft(R) Tablets. The brand product had annual sales of approximately US$2.1 billion for the 12-month period ended...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Mergers, Acquisitions and Ventures Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.